Health care stocks were edging higher premarket Tuesday with the iShares Biotechnology ETF (IBB) advancing by 0.8% and the Health Care Select Sector SPDR Fund (XLV) recently up 0.6%.
Nektar Therapeutics (NKTR) shares were surging by more than 110% after the company said the phase 2b study of investigational rezpegaldesleukin met its primary endpoint in patients with moderate to severe atopic dermatitis.
Amarin (AMRN) shares were up nearly 9% after the company said it signed an exclusive license and supply agreement with Recordati to commercialize Vazkepa in 59 European countries.
Nuvation Bio (NUVB) shares were more than 2% higher after the compay said taletrectinib has been added as a preferred agent in the updated National Comprehensive Cancer Network clinical practice guidelines for non-small cell lung cancer, or NSCLC.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。